Einzeltreffer — DigiBib

Background: Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by widespread eruption of sterile pustules with or without systemic symptoms.

Objectives: This study aimed to describe the demographics of patients with GPP in Central and Eastern Europe (CEE), present the clinical characteristics of individual GPP flares and explore the current treatment landscape.

Methods: Patient demographics were collected at the times of last observation and previous treatment. Characteristics of a patient's last (most recent) and most severe (from all documented episodes) flare were provided at clinician's discretion.

Results: Fifty-eight patients were recruited from 12 centres in nine CEE countries; median (range) age was 61 (16-92) years and 60.3% (35 out of 58) were female. The most common comorbidities were hypertension (43.1% [25 out of 58]) and hyperlipidaemia (32.8% [19 out of 58]). Thirty-four patients (58.6%) presented with concomitant plaque psoriasis before or during the course of GPP. Data from two separate flares were recorded in 26 individuals; in 32 patients, the most recent flare was reported as the most severe. Over 90% of patients with a flare episode classified as most severe by clinicians were hospitalized, with >75% of these individuals having a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of 3 or 4. Systemic symptoms were more common in patients with a GPPGA score of 3 or 4 but were also manifest in individuals with a GPPGA score ≤2. A significant correlation was observed between a combined systemic disease score of clinical and laboratory features and both GPPGA total score (r = 0.385, p < 0.001) and GPPGA pustulation subscore (r = 0.305, p < 0.05).

Conclusions: Considerable heterogeneity in the presentation of GPP flares was observed, both between patients and within-patient. All GPP flares were associated with a significant clinical burden, highlighting the unmet need for accurate and early diagnosis.

Titel:	Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network.
Autor/in / Beteiligte Person:	Wolf, P ; Ceovic, R ; Conrad, C ; Falkensteiner, K ; Graier, T ; Kołt-Kamińska, M ; Marovt, M ; Mateeva, V ; Maul, JT ; Navarini, AA ; Nicolescu, AC ; Ratzinger, G ; Pavlovsky, L ; Sanzharovskaya, M ; Szegedi, A ; Reich, A
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of the European Academy of Dermatology and Venereology : JEADV, 2024-01-27
Veröffentlichung:	Ahead of Print, 2024
Medientyp:	academicJournal
ISSN:	1468-3083 (electronic)
DOI:	10.1111/jdv.19808
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [J Eur Acad Dermatol Venereol] 2024 Jan 27. <i>Date of Electronic Publication: </i>2024 Jan 27. References: Benjegerdes KE, Hyde K, Kivelevitch D, Mansouri B. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl). 2016;6:131-144. ; Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. ; Umezawa Y, Ozawa A, Kawasima T, Shimizu H, Terui T, Tagami H, et al. Therapeutic guidelines for the treatment of generalized pustular psoriasis (GPP) based on a proposed classification of disease severity. Arch Dermatol Res. 2003;295:S43-S54. ; Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13-19. ; Robinson A, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Bebo BF Jr, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279-288. ; Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review. Expert Rev Clin Immunol. 2020;16(3):239-252. ; Prinz JC, Choon SE, Griffiths CEM, Merola JF, Morita A, Ashcroft DM, et al. Prevalence, comorbidities and mortality of generalized pustular psoriasis: a literature review. J Eur Acad Dermatol Venereol. 2022;37:256-273. ; Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620-628. ; Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235-1270. ; Okubo Y, Kotowsky N, Gao R, Saito K, Morita A. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database. J Dermatol. 2021;48(11):1675-1687. ; Lebwohl M, Medeiros R, Mackey R, Harrold LR, Valdecantos WC, Flack M, et al. The disease burden of generalized pustular psoriasis: real-world evidence from CorEvitas' Psoriasis Registry. J Psoriasis Psoriatic Arthritis. 2022;7(2):71-78. ; Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919. ; Yamasaki K, Nakagawa H, Kubo Y, Ootaki K, Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741-751. ; Morita A, Yamazaki F, Matsuyama T, Takahashi K, Arai S, Asahina A, et al. Adalimumab treatment in Japanese patients with generalized pustular psoriasis: results of an open-label phase 3 study. J Dermatol. 2018;45(12):1371-1380. ; Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148-1155. ; Saeki H, Nakagawa H, Nakajo K, Ishii T, Morisaki Y, Aoki T, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355-362. ; Suleiman AA, Khatri A, Oberoi RK, Othman AA. Exposure-response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet. 2020;59(5):575-589. ; Thailand Food and Drug Administration. LUMICEF summary of product characteristics. 2019 [cited 2019 Mar 7]. Available from: https://www.fda.moph.go.th/sites/oss/Drug%20Registration/Lumicef%20Subcutaneous%20Injection%20210%20mg%20Syringe_1C%2015051-61%20(NBC)/LUMICEF%20SUBCUTANEOUS%20_SPC(8-11-19).pdf. ; Imafuku S, Honma M, Okubo Y, Komine M, Ohtsuki M, Morita A, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43(9):1011-1017. ; Mizutani Y, Mizutani YH, Matsuyama K, Kawamura M, Fujii A, Shu E, et al. Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol. J Dermatol. 2020;47(7):e262-e263. ; Okubo Y, Umezawa Y, Sakurai S, Hoshii N, Nakagawa H. Efficacy and safety of certolizumab pegol in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 52-week results. Dermatol Ther (Heidelb). 2022;12(6):1397-1415. ; Beksac B, Adisen E, Gurer MA. Treatment of generalized pustular psoriasis of pregnancy with infliximab. Cutis. 2021;107(3):E2-E5. ; Kim H-S, You H-S, Cho H-H, Kim WJ, Mun J-H, Song M, et al. Two cases of generalized pustular psoriasis: successful treatment with infliximab. Ann Dermatol. 2014;26(6):787-788. ; Kolt-Kaminska M, Zychowska M, Reich A. Infliximab in combination with low-dose acitretin in generalized pustular psoriasis: a report of two cases and review of the literature. Biologics. 2021;15:317-327. ; Bachelez H, Choon S-E, Marrakchi S, Burden AD, Tsai T-F, Morita A, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. ; Gudjonsson J, Reich A, Barker J, Pink A, Reynolds NJ, Griffiths CEM, et al. Imsidolimab, an anti-IL-36 receptor monoclonal antibody, in the treatment of generalized pustular psoriasis: results from a phase 2 trial. European Academy of Dermatology and Venerology (Virtual Congress) 2021. ; Samotij D, Szczęch J, Reich A. Generalized pustular psoriasis: divergence of innate and adaptive immunity. Int J Mol Sci. 2021;22(16):9048. ; Wolf P. How detecting an IL-36Ra mutation in Tunisian families with generalized pustular psoriasis drives an entire field: from a targeted treatment to a new disease score and its psychometric validation. J Eur Acad Dermatol Venereol. 2023;37(7):1260-1. ; FDA U. Spesolimab prescribing information. 2022 [cited 2022 Oct 28]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf. ; Boehringer-Ingelheim. European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares. 2022 [cited 2022 Dec 22]. Available from: https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/european-commission-approves-spevigo-spesolimab-generalized. ; Boehringer-Ingelheim. First-ever treatment aimed at alleviating acute symptoms in pustular psoriasis [media release]. 2022 [cited 2022 Dec 22]. Available from: https://www.boehringer-ingelheim.jp. ; Boehringer-ingelheim. The spesolimab injection approved for marketing. 2022 [cited 2022 Jan 10]. Available from: https://www.ccfdie.org/en/gzdt/webinfo/2022/12/1668877790372263.htm. ; Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical disease measures in generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(1):39-50. ; Burden AD, Bissonnette R, Lebwohl MG, Gloede T, Anatchkova M, Budhiarso I, et al. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). J Eur Acad Dermatol Venereol. 2023;37:1327-1335. ; Choon SE, Lai NM, Mohammad NA, Nanu NM, Tey KE, Chew SF. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676-684. ; Kara Polat A, Alpsoy E, Kalkan G, Aytekin S, Uçmak D, Yasak Güner R, et al. Sociodemographic, clinical, laboratory, treatment and prognostic characteristics of 156 generalized pustular psoriasis patients in Turkey: a multicentre case series. J Eur Acad Dermatol Venereol. 2022;36(8):1256-1265. ; Strober B, Kotowsky N, Medeiros R, Mackey RH, Harrold LR, Valdecantos WC, et al. Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry dermatologists. Dermatol Ther (Heidelb). 2021;11(2):529-541. ; Bachelez H, Massol J, de Pouvourville G, Gloede T, Medina P, Esser D, et al. Characterization of flares in patients with generalized pustular psoriasis - a population-based study from the French National Health Data System database (SNDS). J Am Acad Dermatol. 2021;2021;AB20. ; Bachelez H, Choon S-E, Marrakchi S, Burden AD, Tsai T-F, Morita A, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981-983. ; Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51-64. ; Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):21-29. Grant Information: Boehringer Ingelheim Entry Date(s): Date Created: 20240127 Latest Revision: 20240202 Update Code: 20240202

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Characteristics and management of generalized pustular psoriasis (GPP): Experience from the Central and Eastern Europe (CEE) GPP Expert Network.